Loading
NASDAQHealthcareMedical - Devices
Latest quote
$0.2414
−$0.012 · -4.74%
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
Previous close
$0.2414
−$0.012 · -4.74%
Pre-market
$0.234
−$0.0074 · -3.07%
Oct 9, 9:02 AM ET
Regular session · ET · Market data may be delayed.
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
Day range
Current $0.2414
52-week range
Current $0.2414
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
70
Undervalued
Sentiment
46
Mixed
Risk
75
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
Day range
Current $0.2414
52-week range
Current $0.2414
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 401.95M USD | 458.51M USD | 446.55M USD | 447.61M USD | 429.91M USD |
| Cost of goods sold | 290.49M USD | 311.54M USD | 303.63M USD | 293.65M USD | 269.95M USD |
| Gross profit | 111.45M USD | 146.97M USD | 142.92M USD | 153.96M USD | 159.96M USD |
| Research and development | 37.75M USD | 47.94M USD | 49.73M USD | 57.13M USD | 57.75M USD |
| Selling, general, and administrative | 83.97M USD | 91.19M USD | 92.69M USD | 94.45M USD | 94.06M USD |
| Operating expenses | 137.9M USD | 139.13M USD | 142.42M USD | 151.58M USD | 151.81M USD |
| Interest income | — | 1.19M USD | — | — | — |
| Interest expense | 35.31M USD | 12.95M USD | 11.62M USD | 10.63M USD | 8.13M USD |
| Depreciation and amortization | 7.94M USD | 6.15M USD | 5.91M USD | 4.53M USD | 5.51M USD |
| Operating income | −26.44M USD | 7.84M USD | 504K USD | 2.38M USD | 8.15M USD |
| Net income | −49.19M USD | −1.59M USD | −15.55M USD | −9.28M USD | −5.35M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.00
728.50% upsidePrice history unavailable
High $2.00Average $2.00Low $2.00Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI821.21K0.00%2.3T USD0.03%$379.56-0.39%
Fidelity Enhanced Small Cap ETFFESM362.55K0.01%6.41B USD0.28%$45.25+0.07%
Vanguard Extended Market ETFVXF312.99K0.00%95.4B USD0.05%$233.13-0.15%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM31.35K0.00%688.21M USD0.89%$57.1726+0.08%
Invesco RAFI US 1500 Small-Mid ETFPRFZ29.28K0.00%2.65B USD0.36%$52.82+0.17%Vanguard Morningstar Total Stock Market ETFVTIFidelity Enhanced Small Cap ETFFESMVanguard Extended Market ETFVXFMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMInvesco RAFI US 1500 Small-Mid ETFPRFZAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
